Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Another new myeloma antibody continues to impress…

Home/Research, Supplements/Drugs/Another new myeloma antibody continues to impress…

Another new myeloma antibody continues to impress…

Here is some follow-up on a more well tested anti-myeloma antibody, Elotuzumab–the kind of therapy you will find featured in my new myeloma therapies book.

A number of top myeloma experts, including Doctors Jakubowiak, Jagannath, Durie and Orlowski are big fans.

This article is from an online trade publication called OncLive.com:

Elotuzumab Responses High in Multiple Myeloma Study

Ben Leach
Published Online: Thursday, April 12th, 2012

Elotuzumab, a novel targeted therapy that induces cell breakdown and death in certain cancerous cells, demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

The humanized monoclonal antibody, developed by Bristol-Myers Squibb, targets the cell surface glycoprotein CS1, which is expressed in the tumor cells of more than 95% of patients with multiple myeloma but is minimally expressed in normal cells.

In the ongoing trial, 73 patients previously treated with 1 to 3 prior therapies were enrolled. Patients received lenalidomide and low-dose dexamethasone with either elotuzumab 10 mg/kg or elotuzumab 20 mg/kg.

Of the 36 patients in the elotuzumab 10 mg/kg group, 33 (92%) achieved an objective response rate (ORR), while a 100% ORR was achieved in patients who had received 1 prior therapy before treatment. Of the 37 patients in the elotuzumab 20 mg/kg arm, 27 (73%) achieved an ORR, and an ORR of 82% was seen in patients who received only 1 prior therapy.

After a 14.1-month median follow-up, between 65% and 75% of patients treated with elotuzumab 10 mg/kg combination therapy achieved progression-free survival (PFS). The most common grade 3/4 treatment-emergent adverse events were neutropenia (16%), thrombocytopenia (16%),and lymphopenia (16%).

Two phase III trials incorporating elotuzumab are currently underway. The ELOQUENT 1 study is assessing PFS in previously untreated patients who received elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone, while the ELOQUENT 2 study is assessing PFS in patients with relapsed or refractory multiple myeloma receiving the same dosage.


Lonial S, Jakubowiak AJ, Jagannath S, et al. A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. ASH Annual Meeting. 2011;118(21): abstr 303.

Please note that in this case, patients that received lower doses of elozumab actually did better than those who received higher dosing.  That’s good news!

I’m not sure how long it will take to get this drug FDA approved.  18 months, maybe?  Should be/could be the first real salvage therapy breakthrough that we’ve had in years!

Feel good and keep smiling!  Pat